SUT BEZI SARATONINING TRIPLE-NEGATIV (UCH MARTA MANFIY) SUBTIPIDA NEOADYUVANT KIMYOTERAPIYA FONIDA O‘SMA-INFILTRATSIYA QILUVCHI LIMFOTSITLAR (TILS) DINAMIKASINI BAHOLASH VA UNING METASTAZLANISH XAVFI BILAN BOG‘LIQLIGI
Keywords:
triple-negativ sut bezi saratoni, neoadyuvant kimyoterapiya, o‘sma-infiltratsiya qiluvchi limfotsitlar (TILs), metastazlanish xavfi, patologik to‘liq regressiya.Abstract
Ushbu tezisda triple-negativ sut bezi saratoni (TNSBS) bilan og‘rigan bemorlarda neoadyuvant kimyoterapiya (NAKT) jarayonida o‘smainfiltratsiya qiluvchi limfotsitlar (TILs) darajasining dinamik o‘zgarishi va uning uzoq muddatli metastazlanish xavfi bilan bog‘liqligi tahlil qilinadi. TNSBS o‘zining agressiv kechishi va gormonal nishonlarning yo‘qligi bilan ajralib turadi. Klinik tadqiqotlar ma’lumotlariga ko‘ra, NAKTdan oldingi va keyingi TILs ko‘rsatkichlari immunologik javobning muhim prognostik markeri hisoblanadi. Tezisda TILs darajasining yuqoriligi patologik to‘liq regressiya (pCR) ko‘rsatkichini oshirishi va metastazlanish xavfini sezilarli darajada kamaytirishi haqidagi faktik ma’lumotlar umumlashtirilgan.
References
Foulkes, W. D., Smith, I. E., & Reis-Filho, J. S. (2010). Triplenegative breast cancer. New England Journal of Medicine, 363(20), 1938-1948.
Liedtke, C., Mazouni, C., & Hess, K. R. (2008). Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. Journal of Clinical Oncology, 26(8), 1275-1281.
Denkert, C., von Minckwitz, G., & Brase, J. C. (2015). Tumorinfiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in triple-negative breast cancer. Journal of Clinical Oncology, 33(9), 983-991.
Salgado, R., Denkert, C., & Campbell, C. (2015). The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Annals of Oncology, 26(2), 259-271.
Dieci, M. V., Mathieu, M. C., & Guarneri, V. (2014). Prognostic and predictive value of tumor-infiltrating lymphocytes in carcinoma of the breast. The Breast, 23(2), 115-125.
Ogston, K. N., Miller, I. D., & Payne, S. (2003). A new histological grading system to assess response of breast cancers to primary chemotherapy. The Breast, 12(5), 320-327.
Adams, S., Gray, R. J., & Demaria, S. (2014). Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant trials. Journal of Clinical Oncology, 32(27), 2959-2966.
Hida, A. I., Sagara, Y., & Yotsumoto, D. (2016). Prognostic and predictive impacts of tumor-infiltrating lymphocytes differing between triplenegative and HER2-positive breast cancers treated with neoadjuvant chemotherapy.
Breast Cancer Research and Treatment, 158(3), 429-439.
Loi, S., Michiels, S., & Salgado, R. (2019). Tumor-infiltrating lymphocytes are prognostic in triple-negative breast cancer and predictive for trastuzumab benefit in HER2-positive breast cancer. Annals of Oncology, 30(8), 1280-1288.
Galluzzi, L., Buqué, A., & Kepp, O. (2017). Immunogenic cell death in cancer therapy. Nature Reviews Immunology, 17(2), 97-111.
Mittendorf, E. A., Philips, A. V., & Meric-Bernstam, F. (2014). PD-L1 expression in triple-negative breast cancer. Cancer Immunology Research, 2(4), 361-370.
Schmid, P., Adams, S., & Rugo, H. S. (2018). Atezolizumab and nabpaclitaxel in advanced triple-negative breast cancer. New England Journal of Medicine, 379(22), 2108-2121.
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
Articles published in IQRO — Scientific Methodological Journal are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
Authors retain copyright and grant the journal the right of first publication.
Users may read, download, copy, distribute, print, search, or link to the full texts of articles, provided that the original authors and the journal are properly cited.
Published materials may be used, distributed, and reproduced in any medium, provided that the original work is properly cited.



Uzbekistan
Türkiye
Kazakhstan
Kyrgyzstan
Turkmenistan
Azerbaijan
India
Republic of Korea
Japan
United States of America
Kosovo